AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05355012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5A organizational innovation
Description: This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population.
Study NCT04574024 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NBT-NM108
Description: MS Patients received NBT-NM108 at 60 g/day.
Study NCT05377086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth 3-Dimensional scoliosis exercise
Description: Schroth 3-Dimensional scoliosis exercises
Study NCT05377086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional scoliosis exercise
Description: conventional scoliosis exercise
Study NCT05838170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lotilaner Gel, 2.0%
Description: Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
Study NCT05838170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control gel
Description: Aqueous gel
Study NCT06016062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148/Bevacizumab+RC88 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle
Study NCT06086951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pai.ACT Group
Description: The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
Study NCT06086951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
Study NCT06647342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
Study NCT06647342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
Study NCT06539663 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: OmniLenz®
Description: OmniLenz® applied for 1 week in all patients after development of corneal perforation
Study NCT05448937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion sterilization and tissue repair
Description: Pulp therapy for necrotic primary molars
Study NCT05448937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zinc oxide and eugenol pulpectomy
Description: Pulp therapy for necrotic primary molars
Study NCT06092541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention Group: pericervical anesthesia
Description: Patients assigned to the Intervention Group will receive Pericervical anesthesia before performing Hysteroscopy.~Specifically, for the administration of pericervical analgesia, Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used and pericervical infiltration will be performed at 0.5 cm depth at 3 and 9 hours.
Study NCT06092541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitroux Oxide anesthesia
Description: Patients assigned to the Control Group will receive Nitrous Oxide anesthesia before hysteroscopy
Study NCT04764188 — intervention group
Intervention type: DRUG
Intervention: Alectinib
Description: Participants will receive alectinib in accordance with local clinical practice and local labeling.
Study NCT06477016 — intervention group
Intervention type: DEVICE
Intervention: OsciPulse
Description: Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
Study NCT06477016 — intervention group
Intervention type: DEVICE
Intervention: Intermittent Pneumatic Compression
Description: Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05279742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MANP
Description: Single subcutaneous injection 5 µg/Kg
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: Undergo lymphoscintigraphy scan
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy
Description: Undergo lymphoscintigraphy scan
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06031688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05279742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Oral single dose 97/103 mg
Study NCT05279742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral single dose that contains no active ingredient
Study NCT05279742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral single dose that contains no active ingredient
Study NCT05279742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Placebo
Description: Single subcutaneous injection that contains no active ingredient
Study NCT05279742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection Placebo
Description: Single subcutaneous injection that contains no active ingredient
Study NCT04849832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC
Description: Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
Study NCT04849832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC + tea
Description: Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
Study NCT04849832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
Study NCT04849832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4 + tea
Description: Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
Study NCT05399342 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
Study NCT06552780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENs , ultrasound therapy
Description: effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
Study NCT06211790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, Everolimus and Tislelizumab
Description: Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
Study NCT04837885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
Description: Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
Study NCT05347719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT Intervention
Description: Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
Study NCT04837885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection
Description: intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
Study NCT04837885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUTATHERA® by intra-arterial hepatic (IAH) injection
Description: One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations
Study NCT04837885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scan
Description: Scans after completion of LUTATHERA® treatment injection
Study NCT05762341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESSURE INJURY PREVENTION TRAINING
Description: PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
Study NCT04837911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spirobank Smart
Description: Patients using the Spirobank Smart
Study NCT05942690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual osteopathic intervention
Description: The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
Study NCT06031688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study NCT06031688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Given PO
Study NCT06031688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tepotinib
Description: Given PO
Study NCT06585709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.
Study NCT06585709 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.
Study NCT06585709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: High Ventral Striatal Reactivity
Description: We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define high ventral striatal reactivity as having >mean voxels in the ventral striatum activate
Study NCT06585709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Low Ventral Striatal Reactivity
Description: We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define low ventral striatal reactivity as having \<mean voxels in the ventral striatum activate
Study NCT06559215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Patients will be randomized to receive Exparel intraoperatively via local infiltration. The dosage will be dependent on patient weight.
Study NCT04687774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExaltTM Model D Single-Use Duodenoscope
Description: The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
Study NCT04633252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
Study NCT06340711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: 2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
Study NCT06340711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
Study NCT05332951 — intervention group
Intervention type: OTHER
Intervention: Interpersonal Reactivity Index
Description: Questionnaire to be completed by the patient
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Solo 0.3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Solo 0.3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Solo 1 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Solo 1 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Solo 3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Solo 3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combi 0.3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Combi 0.3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.
Study NCT04842682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combi 1 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.
Study NCT06183788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote cognitive rehabilitation program
Description: Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
Study NCT05879055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: IV infusion
Study NCT05879055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: IV infusion
Study NCT06072768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15-day taper prednisone
Description: The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
Study NCT06072768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150-day taper prednisone
Description: The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
Study NCT05184335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilaroxazine
Description: RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
Study NCT05184335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RP5063 matching Placebo
Study NCT05934019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMPATIA 1
Description: The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.